Guobang Pharma Ltd. (SHA:605507)
China · Delayed Price · Currency is CNY 25.82
+0.38 (1.49%)
Apr 8, 2026, 3:00 PM CST
Guobang Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,011 | 5,867 | 5,327 | 5,704 | 4,493 |
Other Revenue | - | 23.85 | 22.35 | 17.33 | 12.43 |
| 6,011 | 5,891 | 5,349 | 5,721 | 4,505 | |
Revenue Growth (YoY) | 2.05% | 10.12% | -6.49% | 26.98% | 7.11% |
Cost of Revenue | 4,447 | 4,455 | 4,141 | 4,190 | 3,212 |
Gross Profit | 1,565 | 1,435 | 1,209 | 1,531 | 1,294 |
Selling, General & Admin | 375.7 | 345.57 | 365.25 | 339.93 | 297.29 |
Research & Development | 209.83 | 215.05 | 190.51 | 197.54 | 155.27 |
Other Operating Expenses | 17.45 | 25.81 | 30.96 | 31.9 | 23.67 |
Operating Expenses | 602.98 | 598.5 | 579.55 | 581.08 | 478.27 |
Operating Income | 961.88 | 836.84 | 629.3 | 949.97 | 815.55 |
Interest Expense | - | -27.28 | -22.58 | -16.55 | -28.72 |
Interest & Investment Income | 16.99 | 42.89 | 65 | 48.9 | 22.66 |
Currency Exchange Gain (Loss) | - | 32.46 | 22.04 | 58.72 | -14.48 |
Other Non Operating Income (Expenses) | -38.33 | -5.48 | -7.41 | -4.31 | -2.13 |
EBT Excluding Unusual Items | 940.55 | 879.43 | 686.35 | 1,037 | 792.88 |
Gain (Loss) on Sale of Investments | 12.92 | 14.4 | 10.34 | 4.56 | 6.26 |
Gain (Loss) on Sale of Assets | 24.81 | -9.11 | 0.72 | -15.84 | 0.3 |
Asset Writedown | -27.02 | -6.54 | -5.8 | -0.05 | -9.31 |
Other Unusual Items | - | 9.78 | 6.04 | 10.24 | 16.65 |
Pretax Income | 951.26 | 887.97 | 697.65 | 1,036 | 806.78 |
Income Tax Expense | 133.69 | 107.39 | 87.67 | 115.02 | 100.55 |
Earnings From Continuing Operations | 817.57 | 780.58 | 609.98 | 920.62 | 706.23 |
Minority Interest in Earnings | 3.25 | 1.02 | 2.49 | 0.28 | -0.2 |
Net Income | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 |
Net Income to Common | 820.82 | 781.6 | 612.46 | 920.9 | 706.03 |
Net Income Growth | 5.02% | 27.62% | -33.49% | 30.43% | -12.84% |
Shares Outstanding (Basic) | 555 | 558 | 557 | 558 | 512 |
Shares Outstanding (Diluted) | 555 | 558 | 557 | 558 | 512 |
Shares Change (YoY) | -0.66% | 0.27% | -0.24% | 9.09% | 8.01% |
EPS (Basic) | 1.48 | 1.40 | 1.10 | 1.65 | 1.38 |
EPS (Diluted) | 1.48 | 1.40 | 1.10 | 1.65 | 1.38 |
EPS Growth | 5.71% | 27.27% | -33.33% | 19.56% | -19.30% |
Free Cash Flow | 281.57 | 287.29 | -231.68 | 213.92 | -624.23 |
Free Cash Flow Per Share | 0.51 | 0.52 | -0.42 | 0.38 | -1.22 |
Dividend Per Share | - | 0.606 | 0.302 | 0.600 | 0.700 |
Dividend Growth | - | 100.92% | -49.74% | -14.29% | - |
Gross Margin | 26.03% | 24.37% | 22.60% | 26.76% | 28.72% |
Operating Margin | 16.00% | 14.21% | 11.76% | 16.61% | 18.10% |
Profit Margin | 13.65% | 13.27% | 11.45% | 16.10% | 15.67% |
Free Cash Flow Margin | 4.68% | 4.88% | -4.33% | 3.74% | -13.86% |
EBITDA | 1,440 | 1,270 | 950.43 | 1,210 | 1,016 |
EBITDA Margin | 23.95% | 21.55% | 17.77% | 21.15% | 22.56% |
D&A For EBITDA | 477.62 | 432.83 | 321.14 | 260.21 | 200.9 |
EBIT | 961.88 | 836.84 | 629.3 | 949.97 | 815.55 |
EBIT Margin | 16.00% | 14.21% | 11.76% | 16.61% | 18.10% |
Effective Tax Rate | 14.05% | 12.09% | 12.57% | 11.11% | 12.46% |
Revenue as Reported | - | 5,891 | 5,349 | 5,721 | 4,505 |
Advertising Expenses | - | 1.94 | 1.52 | 3.42 | 1.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.